Contexto sectorial
Verastem Inc [VSTM]
Última actualización 24 Jun 2026 @ 16:00 (Exchange is closed)
Último: $3.85
-8.55%
0.00 (↓)
GaG Algo Score™
v1.0
Corto
0.00 (↓)
Medio
-2.21 (↓)
Largo
-2.08 (↓)
COMPRAR
68.97%
rentabilidad 12.83%
VENDER
62.07%
rentabilidad 17.57%
Línea
Datos pivot
Estadísticas pivot
| Métrica | Promedio | Mediana | Desv. est. |
|---|---|---|---|
| Ganancia % | 19.80% | 13.53% | 12.91% |
| Pérdida % | -23.52% | -23.06% | 6.86% |
| Duración | 13.9d | 12d | 9.2d |
| Pivots encontrados | 17 |
| Tramos ganancia/pérdida | 16 (8 Ganancia / 8 Pérdida) |
| Último pivot | Bottom @ $3.62 el 2026-06-03 |
| Cambio desde el último pivot | $0.59 (16.30%) |
Predicción del próximo pivot Último: $3.85
| Próximo tipo previsto | Top |
| Precio previsto (prom.) | $4.34 |
| Precio previsto (mediana) | $4.11 |
| Rango de precio previsto (~68%) | $3.87 - $4.80 |
| Cambio al objetivo promedio | $0.49 (12.64%) |
| Fecha prevista (prom.) | 2026-06-16 |
| Rango de fechas previsto (~68%) | 2026-06-07 - 2026-06-26 |
| Base | Based on 8 historical gains (Avg: 19.80%, Median: 13.53%, StdDev: 12.91%) and duration (Avg: 13.9 days, StdDev: 9.2 days) |
| Nota | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Modest drop for Verastem Inc.
Verastem Inc (VSTM) stock price retreated on Tuesday after the stock fell $-0.0400 (-0.94%) from the previous session on normal volume. The stock fell slightly more than the NASDAQ which was down -0.40%. Yesterday's trading volume was 2.54M shares, worth about $10.70M. This represents 576 818 shares more than the day before. Volume was close to the 10-day average of 2.34M shares.
Verastem Inc signals
There is no conclusive signals given from RSI. The price is below both moving averages, and the short-term average is below the long-term average, confirming a sustained down-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (-16.7%), medium- (-16.7%), and long-term (-16.7%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Verastem Inc Support & Resistance Levels
The stock is trading above the closest support level at $4.20. approximately $0.01000 (0.24%) away. This suggests it is currently acting as a floor, consolidating near support.The sup dis das support s14.2 -
Verastem Inc Evaluation
- Corto puntuación: 0.00
- Medio puntuación: -2.21
- Largo puntuación: -2.08
Flujo de propiedad
GetAGraph InsiderPower
Transacciones
137
Fuerza compradora
12.70M
Fuerza vendedora
1.83M
Fiabilidad
100/100
Compra / venta
6.95
Corr. hist.
-0.66
Última señal
Buy 2026-06-08
Director 60
Executive 47
Officer 30
2026-06-22
Paterson Dan Executive
Sell 20 871
2026-06-22
Calkins Daniel Officer
Sell 4 032
2026-06-22
Calkins Daniel Officer
Sell 57
2026-05-21
Bailey Michael P Director
Buy 108 000
2026-05-21
Bailey Michael P Director
Other
2026-05-21
Bailey Michael P Director
Buy 108 000
Mapa de relación
Resumen de correlación
Contexto de eventos
Volumen y dividendos
Corr. volumen larga
-0.26
Corr. volumen corta
0.04
Positioning pressure
Short interest pressure
Short interest
35.04%
Of outstanding shares
Short float
41.37%
Of tradable float
Days to cover
10.13
Short interest divided by average volume
Squeeze probability
100.00%
+18.71% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
4
EPS misses
6
Avg. surprise
-109.59%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-11-04 | - | - | - | - |
| Q2/2025 | 2025-08-14 | - | $-0.760 | - | - |
| Q1/2025 | 2025-05-13 | $-0.960 | $-0.720 | -33.33% | - |
| Q4/2024 | 2025-03-20 | $-1.330 | $-0.810 | -64.20% | -9.98M |
| Q3/2024 | 2024-11-06 | $-0.600 | $-0.710 | 15.49% | - |
| Q2/2024 | 2024-08-08 | $-0.310 | $-1.060 | 70.75% | 10.00M |
| Q1/2024 | 2024-05-09 | $-1.260 | $-1.160 | -8.62% | - |
| Q4/2023 | 2024-03-14 | $-1.020 | $-0.820 | -24.39% | 114 000 |
Analyst view
Analyst targets
Consensus
$15.40
Median
$18.00
Low
$8.00
High
$18.00
News flow
Latest company news
Market coverage
seekingalpha.com Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers Transcript Jun 23, 2026 businesswire.com VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors Jun 23, 2026 seekingalpha.com Verastem: 'Buy' Positive RAMP-205 Data And Extensive VS-7375 Registration Program Jun 17, 2026 benzinga.com Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer Jun 17, 2026Company releases
Company context
Company profile
Bolsa:
NASDAQ
Sector:
Healthcare
Industria:
Biotechnology
Currency
USD
Verastem Inc is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment A primary asset in its pipeline is VS6766 a novel dual RAFMEK inhibitor that operates by a clamp mechanism This unique action effectively blocks the kinase activity of MEK and disrupts RAFs ability to phosphorylate MEK The company is actively advancing several clinical trials RAMP 201 is an adaptive twopart multicenter randomized openlabel study designed to assess both the efficacy and safety of VS6766 administered alone or in combination with defactinib Defactinib is an oral small molecule inhibitor of focal adhesion kinase FAK and this trial targets patients with recurrent lowgrade serous ovarian cancer Simultaneously Verastem is conducting RAMP 202 a Phase 2 trial focused on evaluating the safety profile of VS6766 combined with defactinib This particular study enrolls patients with nonsmall cell lung cancer NSCLC that harbors KRAS and BRAF mutations specifically after they have undergone treatment with platinumbased regimens and immune checkpoint inhibitors Verastem has also forged strategic partnerships to support its development efforts It holds license agreements with Chugai Pharmaceutical Co Ltd for the development commercialization and manufacturing rights of products incorporating VS6766 Additionally a similar agreement with Pfizer Inc pertains to the research development production and marketing of Pfizers FAK inhibitors for various human applications including therapeutic diagnostic and prophylactic uses Further expanding its collaborations Verastem has a clinical agreement with Amgen Inc to explore the synergistic potential of VS6766 alongside Amgens KRASG12C inhibitor LUMAKRASTM a combination being investigated in the Phase 12 RAMP 203 trial Founded in 2010 Verastem Inc maintains its corporate headquarters in Needham Massachusetts
Navigation